x
Filter:
Filters applied
- JLR Patient-Oriented and Epidemiological Research
- Meikle, Peter JRemove Meikle, Peter J filter
- Giral, PhilippeRemove Giral, Philippe filter
Publication Date
Please choose a date range between 2015 and 2020.
Keyword
- lipidomics2
- low density lipoprotein2
- metabolic syndrome2
- pitavastatin2
- antioxidative activity1
- ceramides1
- cholesterol1
- high density lipoprotein 31
- isopycnic density gradient ultracentrifugation1
- lipoprotein-associated phospholipase A21
- liquid chromatography electrospray ionization-tandem mass spectrometry1
- low density lipoprotein subclass heterogeneity1
- lysophosphatidylcholine1
- metabolic syndrome disease1
- obesity1
- omega-3 fatty acids1
- oxidative stress1
- phospholipid hydroxides1
- pitavastatin calcium1
- plasmalogens1
JLR Patient-Oriented and Epidemiological Research
3 Results
- Patient-Oriented and Epidemiological ResearchOpen Access
LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL
Journal of Lipid ResearchVol. 61Issue 6p911–932Published online: April 15, 2020- M. John Chapman
- Alexina Orsoni
- Ricardo Tan
- Natalie A. Mellett
- Anh Nguyen
- Paul Robillard
- and others
Cited in Scopus: 24Atherogenic LDL particles are physicochemically and metabolically heterogeneous. Can bioactive lipid cargo differentiate LDL subclasses, and thus potential atherogenicity? What is the effect of statin treatment? Obese hypertriglyceridemic hypercholesterolemic males [n = 12; lipoprotein (a) <10 mg/dl] received pitavastatin calcium (4 mg/day) for 180 days in a single-phase unblinded study. The lipidomic profiles (23 lipid classes) of five LDL subclasses fractionated from baseline and post-statin plasmas were determined by LC-MS. - Patient-Oriented and Epidemiological ResearchOpen Access
Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia
Journal of Lipid ResearchVol. 57Issue 11p2073–2087Published online: August 31, 2016- Alexina Orsoni
- Patrice Thérond
- Ricardo Tan
- Philippe Giral
- Paul Robillard
- Anatol Kontush
- and others
Cited in Scopus: 23Atherogenic mixed dyslipidemia associates with oxidative stress and defective HDL antioxidative function in metabolic syndrome (MetS). The impact of statin treatment on the capacity of HDL to inactivate LDL-derived, redox-active phospholipid hydroperoxides (PCOOHs) in MetS is indeterminate. Insulin-resistant, hypertriglyceridemic, hypertensive, obese males were treated with pitavastatin (4 mg/day) for 180 days, resulting in marked reduction in plasma TGs (−41%) and LDL-cholesterol (−38%), with minor effects on HDL-cholesterol and apoAI. - Patient-Oriented and Epidemiological ResearchOpen Access
Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
Journal of Lipid ResearchVol. 56Issue 12p2381–2392Published online: October 20, 2015- Peter J. Meikle
- Gerard Wong
- Ricardo Tan
- Philippe Giral
- Paul Robillard
- Alexina Orsoni
- and others
Cited in Scopus: 36The impact of statin treatment on the abnormal plasma lipidome of mixed dyslipidemic patients with metabolic syndrome (MetS), a group at increased risk of developing diabetes, was evaluated. Insulin-resistant hypertriglyceridemic hypertensive obese males (n = 12) displaying MetS were treated with pitavastatin (4 mg/day) for 180 days; healthy normolipidemic age-matched nonobese males (n = 12) acted as controls. Statin treatment substantially normalized triglyceride (−41%), remnant cholesterol (−55%), and LDL-cholesterol (−39%), with minor effect on HDL-cholesterol (+4%).